A Korean Family of Hypokalemic Periodic Paralysis with Mutation in a Voltage-gated Calcium Channel (R1239G)

Hypokalemic periodic paralysis (HOPP) is a rare disease characterized by reversible attacks of muscle weakness accompanied by episodic hypokalemia. Recent molecular work has revealed that the majority of familial HOPP is due to mutations in a skeletal muscle voltage-dependent calcium-channel: the dihydropyridine receptor. We report a 13-yr old boy with HOPP from a family in which 6 members are affected in three generations. Genetic examination identified a nucleotide 3705 C to G mutation in exon 30 of the calcium channel gene, CACNA1S. This mutation predicts a codon change from arginine to glycine at the amino acid position #1239 (R1239G). Among the three known mutations of the CACNA1S gene, the R1239G mutation was rarely reported. This boy and the other family members who did not respond to acetazolamide, showed a marked improvement of the paralytic symptoms after spironolactone treatment.

Key Words: Hypokalemic Periodic Paralysis; Calcium Channels; Mutation; Spironolactone; Children

INTRODUCTION

Familial hypokalemic periodic paralysis (HOPP) is an autosomal dominant disorder characterized by episodic attacks of muscle weakness accompanied by episodic hypokalemia. Recent molecular work has revealed that the majority of familial HOPP is due to mutations in a skeletal muscle voltage-dependent calcium-channel: the dihydropyridine receptor. We report a 13-yr old boy with HOPP from a family in which 6 members are affected in three generations. Genetic examination identified a nucleotide 3705 C to G mutation in exon 30 of the calcium channel gene, CACNA1S. This mutation predicts a codon change from arginine to glycine at the amino acid position #1239 (R1239G). Among the three known mutations of the CACNA1S gene, the R1239G mutation was rarely reported. This boy and the other family members who did not respond to acetazolamide, showed a marked improvement of the paralytic symptoms after spironolactone treatment.

Key Words: Hypokalemic Periodic Paralysis; Calcium Channels; Mutation; Spironolactone; Children

CASE REPORT

A 13-yr old boy presented with near-daily attacks of mild to severe paralysis for the past 8 yr. The symptoms mainly appeared in the morning and he usually awakened with weakness of the four limbs to the point of difficulty in sitting and walking. After the paralytic episode in the morning, he was free of symptoms in the afternoon, but eating high-sodium or carbohydrate foods and rest after vigorous exercise made him weak or completely paralyzed again at any time. In family history, his mother (41 yr old), maternal-grandmother (81 yr old), maternal aunt (55 yr old) and her two sons (the patient’s cousins, 23 and 27 yr old) were also suffering from similar attacks of weakness or paralysis throughout their lives (Fig. 1). The severity and frequency of attacks of grandmother and mother has decreased with age. Two cousins of the proband were diagnosed HOPP 8 yr ago at our hospital. They were treated with acetazolamide and potassium supplements. Because there is no effect of such treatment, they stopped taking the drugs and they were lost further medical support.

On admission, the proband showed non-specific findings in physical examination, radiologic and laboratory findings including muscle enzymes. During paralytic episodes, the patient showed low serum potassium levels (3.2 mEq/L vs. 4.4 mEq/L between attack) and hypokalemic ECG findings, such as ST segment depression and U-wave. There was no myotonia in EMG findings. DNA examination identified a nucleotide 3705 C to G mutation in exon 30 of CACNA1S gene (Table 1). This mutation predicts codon change from
arginine to glycine at amino acid position #1239 in the calcium channel gene (Fig. 2). The patient was treated with spironolactone (25 mg b.i.d.), and he showed a dramatic improvement in his symptoms within 2 days. Other affected members of the family, including two cousins of the proband, have also started taking spironolactone. They could also themselves awaken refreshed and move at their will throughout the day.

**DISCUSSION**

Periodic paralyses constitute a group of human hereditary muscle disorders. Based on the variations of serum potassium levels during attacks, they can classify as HOPP or hyperkalemic periodic paralysis. Both are inherited via autosomal dominant mode with a high penetrance. HOPP is the most frequent cause of periodic paralysis. The prevalence of HOPP has been estimated at 1/100,000. Although most individuals diagnosed with HOPP in Western countries were familial types, sporadic types with or without underlying diseases, such as thyrotoxicosis and renal tubular acidosis have been reported in Korea (14-16).

Three mutations of CACNL1A3 gene are known in familial HOPP (7-9). CACNA1S encodes the 1-subunit of a skeletal muscle voltage-gated calcium channel termed the dihydropyridine (DHP) receptor. This channel is composed of five subunits called α, β, γ, and δ. The α1-subunit constitutes the ion-conducting pore, and contains the receptor for dihydropyridine and other ligands (17, 18), whereas the other subunits regulate the function of the α1-subunit of the channel. The α1-subunit is composed of four transmembrane domains (I to IV), each of them containing six transmembrane helices (S1 to S6) (Fig. 2). The amino-acid substitutions in the three mutations are as follows: the replacement of a positively-charged arginine in position 528 in segment S4 of domain II by a weakly-positive histidine (R528H) and an arginine in position 1239 in the S4 segment of the fourth domain by either an histidine or a glycine (R1239H and R1239G) (7, 9). Molecular studies in Caucasian families demonstrated that R528H and R1239H are predominant mutations (4, 10), whereas the R1239G mutation was only found in a single family (9). The molecular diagnosis for familial HOPP was possible using PCR amplification of genomic DNA followed by restriction-enzyme digestion. By this method, the proband identified that the rare R1239G mutation inherited in his family (Fig. 2, Table 1).

Recently, mutations in the sodium channel gene (SCN4) in HOPP were reported. The structure of the sodium channel is similar to that of the calcium channel and is composed of 4 domains each with 6 segments. These mutations were found in the domain II of the S4 segment like R528H and R1239H are predominant mutations (4, 10). Whereas the R1239G mutation was only found in a single family (9). The molecular diagnosis for familial HOPP was possible using PCR amplification of genomic DNA followed by restriction-enzyme digestion. By this method, the proband identified that the rare R1239G mutation inherited in his family (Fig. 2, Table 1).

**Table 1. Results of DNA analysis in the proband**

| Mutation | Restriction enzyme | Control used | Patient results |
|----------|--------------------|--------------|-----------------|
| R528H    |MspA I, cuts normal | heterozygote | normal          |
| R1239G   |Sau96 I, cuts normal| heterozygote | heterozygote    |
| R1239H   |Bsp LU III, cuts mutant| heterozygote| normal          |

*Controls used in this test are the corresponding mutants.

---

Fig. 1. Pedigree of the HOPP family. The dark symbols are affected individuals. The proband is indicated by an arrow. The age of the family members is designated by the number.

Fig. 2. Schematic diagram of the DHP receptor α1-subunit composed of four domains of an internal homology (DI to DIV) connected by intracellular loops. The R1239G mutation substitutes a positively-charged arginine located within segment DIVS4 by a neutral glycine.
ications also seems to depend upon the mutations underlying periodic paralysis (4, 13). The acetazolamide, a carbonic anhydrase inhibitor, has been considered highly effective in most HOPP patients (19-21). However, several patients with the R672G SCN4A mutation (4) and a patient with the R672S SCN4A mutation (13) showed an exacerbation of the symptoms after acetazolamide treatment. Although we did not perform DNA analysis for two cousins of the proband, they experienced an exacerbation of symptoms with acetazolamide treatment 8 yr ago. However, it has not been determined yet that the R1239G mutation is associated with acetazolamide resistance. Our patients showed a remarkable improvement of symptoms with spironolactone treatment. Spironolactone and its derivatives are alternatives to acetazolamide if it is not effective after the empirical initial use (22-26). The action of the aldosterone antagonists on HOPP is not known. The beneficial effects on HOPP cannot be explained by antagonism to the action of aldosterone on the renal or enteric excretion of sodium and potassium (22). Although recent studies have demonstrated that mutations in the calcium- and sodium channels cause HOPP, the mechanism of these channels in the pathophysiology of HOPP has not clearly been defined. Several complications during the clinical courses have been reported. Vascular myopathy, unexpected acute paralysis or cardiac arrhythmia with hypokalemia, and possibly malignant hyperthermia associated with anesthesia have been reported (27, 28).

In conclusion, genetic diagnosis of familial HOPP is very useful for making a definitive diagnosis, providing genetic counseling for the family members and as well as for providing the appropriate treatment.

ACKNOWLEDGEMENT

We are grateful to Dr Katherine B Sims, Massachusetts General Hospital, Harvard University, for performing DNA analysis.

REFERENCES

1. Talb H. Periodic paralysis. Medicine 1941; 20: 85-96.
2. Jen J, Ptacek L. Channelopathies. In: Scrivner CR, Beaudet AL, Sly WS, Valle D (eds). Metabolic and molecular bases of inherited disease, 8th ed., New York: McGraw-Hill, 2001; 5223-38.
3. Lapie P, Lory P, Fontaine B. Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. Neuromusc Disord 1997; 7: 234-40.
4. Sternberg D, Maisonneuve T, Jurkat-Rott K, Nicole S, Launay E, Chauveau D, Tabti N, Lehmann-Horn F, Hainque B, Fontaine B. Hypokalemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001; 124: 1091-9.
5. Caciotti A, Morrone A, Domenici R, Donati MA, Zammarchi E. Severe prognosis in a large family with hypokalemic periodic paralysis. Muscle Nerve 2003; 27: 165-9.
6. Bulman DE, Scoggin KA, van Oene MD, Nicolls MW, Hahn AF, Tollar LL, Ebers GC. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 1999; 53: 1932-6.
7. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, Heine R, Gregg RG, Hogan K, Powers PA, Lapie P, Vale-Santos JE, Weissenbach J, Fontaine B. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet 1994; 3: 1415-9.
8. Fontaine B, Vale Santos JM, Jurkat-Rott K, Reboul J, Plassart E, Rime CS, Elbaz A, Heine R, Guimaraes J, Weissenbach J, Baumann N, Fardeau M, Lehmann-Horn F. Mapping of the hypokalemic periodic paralysis to chromosome 1q31-q32 in three European families. Nat Genet 1994; 6: 267-72.
9. Ptacek LJ, Tawil R, Griggs RC, Engel AG, Layzer RB, Lacykecinis H, McManis PG, Santiago L, Moore M, Fouad G, Bradley P, Lepffert MF. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77: 863-8.
10. Elbaz A, Vale-Santos J, Jurkat-Rott K, Lapie P, Ophoff RA, Bady B, Links TP, Puscan C, Vila A, Monnier N. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype-phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet 1995; 56: 374-80.
11. Grosson CS, Esteban J, McKenna-Yasek D, Gusella JF, Brown RH. Hypokalemic periodic paralysis mutations: confirmation of mutation and analysis of founder effect. Neuromusc Disord 1996; 6: 27-31.
12. Fouad G, Dalakas M, Servidei S, Mendell JR, Van den Bergh P, Angelini C, Alderson K, Griggs RC, Tawil R, Gregg R, Hogan K, Powers PA, Weinberg N, Malonee W, Ptacek LJ. Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis. NeuroMusc Disord 1997; 7: 33-8.
13. Bendahhou S, Cummins TR, Hahn AF, Langlois S, Waxman SG, Ptacek LJ. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol 2001; 50: 417-20.
14. Seo SK, Lee GH, Jeong HY, Kim SW, Kim KH. A case of familial hypokalemic periodic paralysis. J Korean Pediatr Soc 1998; 32: 1012-6.
15. Kim KK, Lee JH, Lee SS, Roh JK, Lee SB, Myung H. Two cases of familial hypokalemic periodic paralysis. J Korean Neurol Sci 1990; 8: 180-4.
16. Kim SH, Kim UK, Chue JI, Kim DJ, Oh HY, Kim BJ, Lee CC. Identification of mutations including de novo mutations in Korean patients with hypokalemic periodic paralysis. Nephrol Dial Transplant 2001; 16: 939-44.
17. Catteral WA. Structure and function of voltage-sensitive ion channels. Science 1988; 242: 50-61.
18. Perez-Reyes E, Kim HS, Lacerda AE, Horne W, Wei XY, Rampe D, Campbell KP, Brown AM, Birnhauser L. Induction of calcium currents by the expression of the alpha-subunit of the dihydropyridine receptor from skeletal muscle. Nature 1989; 340: 233-6.
19. Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Ann Intern Med 1970; 73: 39-48.
20. Tricarico D, Barbieri M, Camerino DC. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000; 48: 304-12.
21. Links TP, Smit AJ, Molenaar WM, Zwarts MJ, Oosterhuis HJ. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci 1994; 122: 33-43.
22. Poskanzer DC, Kerr DN. Periodic paralysis with response to spironolactone. Lancet 1961; 2: 511-3.
23. Torres CF, Griggs RC, Moxley RT, Bender AN. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology 1981; 31: 1423-8.
24. Rischbieth RH. Hypokalemic periodic paralysis unresponsive to acetazolamide. Clin Exp Neurol 1981; 18: 87-90.
25. Vern BA, Danon MJ, Hanlon K. Hypokalemic periodic paralysis with unusual responses to acetazolamide and sympathomimetics. J Neurol Sci 1987; 81: 159-72.
26. Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Pucek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC. Randomized trials of dichlorphenamide in the periodic paralysis. Working Group on Periodic Paralysis. Ann Neurol 2000; 47: 46-53.
27. Lambert C, Blanloeil Y, Horber RK, Berard L, Reyford H, Pinaud M. Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 1994; 79: 1012-4.
28. Horton B. Anesthetic experiences in a family with hypokalemic familial periodic paralysis. Anesthesiology 1977; 47: 308-10.